Biohaven Announces Late-Breaking Oral Presentation Of Rimegepant Zydis® ODT Phase 3 Results At American Academy Of Neurology (AAN) 2019 Annual Meeting And New Data Release At Investor Event
Advertisement
- Late-Breaking oral presentation accepted at AAN: First public disclosure of the complete rimegepant Zydis® oral fast-dissolve tablet (ODT) Phase 3 clinical trial results showing single-dose, rapid and durable migraine relief
